Risk factors
RenovoRx (RNXT) risk factors
Item 1A of every RenovoRx, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks75 new68 dropped
RenovoCath generated $1.1 million in 2025, but commercialization remains limited and the company still reported an $11.2 million net loss.
Filed Mar 30, 2026 - FY2024 10-K risk factors68 risks
RenovoRx faces significant financial losses and relies heavily on the success of its Phase III TIGeR-PaC clinical trial. The company is newly commercializing the RenovoCath device on a standalone basis with no prior operating experience. Substantial additional capital will be required to develop lead product candidate IAG and commercialize RenovoCath.
Filed Apr 01, 2025